ENT Private Equity: What Otolaryngologists Should Know
ENT Private Equity: What Otolaryngologists Should Know
ENT private equity activity has grown steadily, and many otolaryngologists have now received a call, letter, or conference invitation from a PE-backed platform. Some see an opportunity to monetize years of work and share administrative burdens. Others worry about losing clinical autonomy. Most simply want to understand what is being offered before deciding.
This guide explains why private equity firms are interested in otolaryngology practices, how deals are commonly structured, what research has found so far, and what to ask before signing a letter of intent. It is educational, and it is meant to help you prepare for conversations with independent professionals.
Key takeaways
Published research shows private equity acquisitions of US otolaryngology practices increased over the past decade.
ENT practices attract investors because of ancillary service lines such as audiology, hearing aids, allergy, imaging, and sleep services.
The headline price is only part of a deal. Rollover equity, earn-outs, compensation changes, and non-competes shape the real outcome.
Independent legal, tax, and valuation review before signing a letter of intent can help you compare offers on equal terms.
How common are ENT private equity deals?
Otolaryngology was a later target for private equity than specialties such as dermatology, but activity has grown. A study in Otolaryngology–Head and Neck Surgery identified 23 otolaryngology practices acquired by 11 private equity firms from 2015 through 2021, with annual acquisitions rising from 1 in 2015 to 8 in 2021. The acquired practices represented 204 otolaryngologists across 132 locations (Otolaryngology–Head and Neck Surgery, 2023).
A separate 2025 study in OTO Open identified 25 otolaryngology practices acquired between 2018 and 2023 and found that advanced practice providers grew from 19.1% to 24.6% of clinicians at acquired practices (OTO Open, 2025).
Researchers have also examined payments. A 2025 analysis of Medicare data reported that average payment per procedure at practices after private equity acquisition was higher than at comparison non-PE practices, $105.2 versus $91.3 (Otolaryngology–Head and Neck Surgery, 2025). Earlier commentary in JAMA Otolaryngology–Head & Neck Surgery discussed the potential implications of these acquisitions for physicians and patients (JAMA Otolaryngology, 2019).
These studies are useful context, but every deal and every practice is different.
Why private equity firms target ENT practices
Ancillary service lines
ENT practices often include audiology and hearing aid sales, allergy testing and immunotherapy, in-office CT imaging, sleep services, and in-office procedures. These lines can create diversified revenue that investors value.
Fragmented market
Many otolaryngology practices are small or mid-sized and independently owned. Private equity platforms grow by acquiring an initial "platform" practice and then adding smaller "add-on" practices.
Scale and administrative leverage
Investors look to centralize billing, purchasing, IT, recruiting, and payer contracting across many locations.
An eventual exit
Private equity funds usually plan to sell or recapitalize the platform after several years. The 2023 study noted that PE firms typically sell or recapitalize within about three to seven years. That second transaction can affect physicians who hold rollover equity.
If your practice is considering audiology or hearing aid sales, our article on adding audiology to an ENT practice covers the licensing and sales rules involved.
How ENT private equity deals are commonly structured
Most transactions follow a similar pattern, though terms vary widely.
The management services structure
Because many states restrict non-physician ownership of medical practices under the corporate practice of medicine doctrine, deals often use a management services organization (MSO). The investor buys the non-clinical assets and enters a long-term management agreement with a physician-owned professional entity. The details of this structure determine how much control physicians keep over clinical and business decisions.
Purchase price and earnings
Offers are often based on a multiple of adjusted earnings after physician compensation is reset. Physicians agree to lower future compensation in exchange for an upfront payment, sometimes called a "scrape." Understanding how the scrape is calculated is essential.
Cash and rollover equity
Part of the price is typically paid in cash at closing and part as rollover equity in the platform. Rollover equity can increase in value if the platform is sold later at a higher price, but it is illiquid and carries risk.
Earn-outs and holdbacks
Some deals include payments tied to future performance or held in escrow to cover post-closing issues.
Employment agreements and non-competes
Selling physicians usually sign multi-year employment agreements with production expectations and restrictive covenants. Our earlier article on non-compete lawyers for ENTs explains why these terms deserve careful review.
Questions to ask before signing a letter of intent
A letter of intent may be described as non-binding, but it often sets key economic terms and exclusivity periods. Before signing, consider:
What is the practice worth on its own? An independent valuation gives you a benchmark.
How is the scrape calculated, and what will my post-closing compensation be?
How much is cash versus rollover equity, and what rights come with the equity?
Who controls clinical decisions, hiring, scheduling, and APP utilization?
What happens to ancillaries, such as audiology and allergy, after the deal?
How are younger physicians and future partners treated? Junior partners may receive far less value than senior owners.
What are the non-compete terms, and what happens if I leave early?
How will the cash and equity components be treated? An independent CPA can help you understand this.
What happens at the platform's next sale?
Alternatives to a private equity sale
Private equity is one option, not the only one. Otolaryngologists also consider:
Hospital or health system employment
Merging with another independent ENT group to gain scale
Joining a physician-led MSO that provides services without a full sale
An internal transition to younger partners over time
Staying independent and improving operations
Each path has different economic, legal, and personal trade-offs. Our article on business structure for ENTs covers some of the structural choices. If you are still deciding whether to sell at all, review these signs it's time to sell your ENT practice.
Preparing your practice, whatever you decide
Clean up financial statements and normalize owner compensation
Document compliance for ancillary services
Review payer contracts and leases for change-of-control clauses
Align partners on goals before an offer arrives
Strengthen your online presence and referral relationships
A clear, well-organized website is part of that preparation, and our guide to ENT website design explains how to structure services patients can navigate.
Frequently asked questions
Why are private equity firms buying ENT practices?
Investors are drawn to ancillary service lines, a fragmented market of independent practices, and the opportunity to centralize administrative functions across locations.
What is rollover equity in an ENT private equity deal?
It is the portion of the purchase price paid in ownership of the buyer's platform rather than cash. Its value depends on the platform's future performance and sale.
Will I lose clinical autonomy after a private equity sale?
It depends on the deal structure, management agreement, and employment terms. Physicians should review governance and control provisions carefully before signing.
How long do ENT private equity deals last?
Selling physicians usually sign multi-year employment agreements, and research indicates PE firms typically sell or recapitalize platforms within about three to seven years.
Can you introduce me to someone who can review an offer?
Yes. We are an introduction service. We can introduce you to an independent healthcare transaction attorney, CPA, or valuation professional we partner with.
Request an introduction
If you have received a private equity offer or want to understand your options, call (972) 616-4581 to request an introduction to an independent professional we partner with. Learn more about exit planning and business and legal planning, or browse the Knowledge Center.
This article is general information, not tax, legal, or investment advice. Please read our disclaimer.
